Correlation between phospholipase of Candida albicans and resistance to fluconazole

Mycoses

Volumn 55, Issue 1, 2012, Pages 50-55

  Ying, Su ^a   Chunyang, Li ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Candida albicans; Fluconazole resistance; MRNA; Phospholipase; Protein

Indexed keywords

FLUCONAZOLE; LYSOPHOSPHOLIPASE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EGG YOLK; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; FUNGAL STRAIN; FUNGAL VIRULENCE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; WESTERN BLOTTING;

ANIMALS; ANTIFUNGAL AGENTS; BLOTTING, WESTERN; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; ENZYME ACTIVATION; FEMALE; FLUCONAZOLE; LYSOPHOSPHOLIPASE; MALE; MICE; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; VIRULENCE;

CANDIDA; CANDIDA ALBICANS; MUS;

EID: 83655163928     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02024.x     Document Type: Article

References (29)

1. Wright WL, Wenzel RP. Nosocomial Candida. Epidemiology, transmission, and prevention. Infect Dis Clin North Am 1997; 11: 411-25.
2. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
3. Grisaru-Soen G, Sweed Y, Lerner-Geva L et al. Nosocomial bloodstream infections in a pediatric intensive care unit: 3-year survey. Med Sci Monit 2007; 13: 251-7.
4. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-44.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
6. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010; 14: 954-66.
7. Cutler JE. Putative virulence factors of Candida albicans. Annu Rev Microbiol 1991; 45: 187-218.
8. Ghannoum MA, Abu-Elteen KH. Pathogenicity determinants of Candida. Mycoses 1990; 33: 265-82.
9. Yang YL. Virulence factors of Candida species. J Microbiol Immunol Infect 2003; 36: 223-8.
10. Ibrahim AS, Mirbod F, Filler SG et al. Evidence implicating phospholipase as a virulence factor of Candida albicans. Infect Immun 1995; 63: 1993-8.
11. Leidich SD, Ibrahim AS, Fu Y et al. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem 1998; 273: 26078-86.
12. Mukherjee PK, Seshan KR, Leidich SD, Chandra J, Cole GT, Ghannoum MA. Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo. Microbiology 2001; 147: 2585-97.
13. Skrodeniene E, Dambrauskiene A, Vitkauskiene A. Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital. Medicina (Kaunas) 2006; 42: 294-9.
14. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994; 34: 659-68.
15. Becker JM, Henry LK, Jiang W, Koltin Y. Reduced virulence of Candida albicans mutants affected in multidrug resistance. Infect Immun 1995; 63: 4515-8.
16. Wu T, Wright K, Hurst SF, Morrison CJ. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans Isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 2000; 44: 1200-8.
17. Fekete-forgacs K, Gyure L, Lenkey B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses 2000; 43: 273-9.
18. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 1982; 20: 7-14.
19. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Differential expression of Candida albicans phospholipase B (PLB1) under various environmental and physiological conditions. Microbiology 2003; 149: 261-7.
20. Barrett-Bee K, Hayes Y, Wilson RG, Ryley JF. A comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts. J Gen Microbiol 1985; 131: 1217-21.
21. Naglik JR, Rodgers CA, Shirlaw PJ et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003; 188: 469-79.
22. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
23. Odds FC. Resistance of clinically important yeasts to antifungal agents. Int J Antimicrob Agents 1996; 6: 145-7.
24. Lay J, Henry LK, Clifford J, Koltin Y, Bulawa CE, Becker JM. Altered expression of selectable marker URA3 in gene-disrupted Candida albicans strains complicates interpretation of virulence studies. Infect Immun 1998; 66: 5301-6.
25. Lyon JP, de Resende MA. Correlation between adhesion, enzyme production, and susceptibility to fluconazole in Candida albicans obtained from denture wearers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 632-8.
26. Graybill JR, Montalbo E, Kirkpatrick WR, Luther MF, Revankar SG, Patterson TF. Fluconazole versus Candida albicans: a complex relationship. Antimicrob Agents Chemother 1998; 42: 2938-42.
27. Samaranayake YH, Dassanayake RS, Jayatilake JA et al. Phospholipase B enzyme expression is not associated with other virulence attributes in Candida albicans isolates from patients with human immunodeficiency virus infection. J Med Microbiol 2005; 54: 583-93.
28. Banno Y, Yamada T, Nozawa Y. Secreted phospholipases of the dimorphic fungus, Candida albicans; separation of three enzymes and some biological properties. Sabouraudia 1985; 23: 47-54.
29. Mirbod F, Banno Y, Ghannoum MA et al. Purification and characterization of lysophospholipase-transacylase (h-LPTA) from a highly virulent strain of Candida albicans. Biochim Biophys Acta 1995; 1257: 181-8.